Patents Issued in December 8, 2020
  • Patent number: 10857163
    Abstract: The invention provides compositions containing isomerically pure forms of neurosteroids that permit preferential modulation of different subtypes of GABAA receptors, such as preferential modulation of ?4?3? GABAA receptors over ?1?2?2 GABAA receptors. The invention also provides methods of treating GABAA disorders using such compositions.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: December 8, 2020
    Assignee: ATHENEN THERAPEUTICS, INC.
    Inventors: Andrew D. Levin, Neil Buckley
  • Patent number: 10857164
    Abstract: The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: December 8, 2020
    Assignee: UNION therapeutics A/S
    Inventors: Morten Otto Alexander Sommer, Ramus Vendler Toft-Kehler, Daniel Jean Jacques Simon
  • Patent number: 10857165
    Abstract: Disclosed herein are methods and compositions for removing or displacing bisphosphonates in skeletal tissue.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: December 8, 2020
    Assignees: The Regents of the University of California, BioVinc LLC, University of Southern California
    Inventors: Frank Hallock Ebetino, Ichiro Nishimura, Shuting Sun, Mark Walden Lundy, Akishige Hokugo, Charles McKenna, Keivan Sadrerafi
  • Patent number: 10857166
    Abstract: Flavonoids that are isolated from plant material of the genus Cecropia can be used to perturb G-protein coupled receptors in a mammalian cell. In some instances, one or more flavonoids may interact with one or more of the G-protein coupled receptors to transiently increase the concentration of cytosolic calcium. Administration of the isolated flavonoids can be used to treat hypertension, to protect the integrity of blood vessels and related conditions.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: December 8, 2020
    Assignee: INSTITUTO DE INVESTIGACIONES CIENTIFICAS Y SERVICIOS DE ALTA TECNOLOGIA (INDICASAT AIP)
    Inventors: Catherina C. Caballero-George, Andres Rivera Mondragon
  • Patent number: 10857167
    Abstract: Provided herein are compositions and methods related to use of oligosaccharides, such as 2?-fucosyllactose, for increasing weight gain in a subject. In some aspects the compositions and methods are for use in infants, such as premature infants or infants having intestinal failure.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: December 8, 2020
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Ardythe L. Morrow, Michael A. Helmrath, Ethan Mezoff
  • Patent number: 10857168
    Abstract: This invention relates to a method and composition for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: December 8, 2020
    Assignee: GLYCOM A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs
  • Patent number: 10857169
    Abstract: Powder formulations for inhalation which comprise microparticles containing an antibiotic and magnesium stearate are useful for the treatment of bacterial infections associated with certain pulmonary diseases.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: December 8, 2020
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: David Morton, Qi Zhou, Rossella Musa
  • Patent number: 10857170
    Abstract: A SIRT6 activating molecule as shown in Tables 1-3 or a compound according to a pharmacophore as described herein.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: December 8, 2020
    Assignee: SirTLab Corporation
    Inventors: Haim Yosef Cohen, Yariv Kanfi
  • Patent number: 10857171
    Abstract: The stable pharmaceutical compositions comprising a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: December 8, 2020
    Assignee: WOCKHARDT LIMITED
    Inventors: Mohammad Ajmal Shareef, Mrutunjaya Sahu, Ajaykumar Handa
  • Patent number: 10857172
    Abstract: Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: December 8, 2020
    Assignee: ChromaDex, Inc.
    Inventors: Ryan Dellinger, Troy Rhonemus, Mark Morris, Dietrich Conze, Amy Boileau
  • Patent number: 10857173
    Abstract: The present invention provides methods for treating or suppressing tumor metastasis at a site distinct from the bladder in an individual having a urothelial carcinoma of lower tract, comprising locally delivering to the bladder an effective amount of a chemotherapeutic agent (such as gemcitabine), wherein the chemotherapeutic agent is delivered continuously to the bladder for a sustained period of time (such as at least 24 hours).
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: December 8, 2020
    Assignee: TARIS Biomedical LLC
    Inventor: Dennis Giesing
  • Patent number: 10857174
    Abstract: Disclosed are morpholino oligonucleotides that can be used to silence expression of MGMT, pharmaceutical compositions that include said morpholino oligonucleotides, and methods of using said morpholino oligonucleotides in the treatment of cancer, particularly methods that involve the use of radiation to deliver said morpholino oligonucleotides.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: December 8, 2020
    Assignees: UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Prakash Ambady, Jeffrey Wu, Edward Neuwelt
  • Patent number: 10857175
    Abstract: The application describes compositions that include maltosyl-isomalto-oligosaccharides with a desirable mass average molecular weight distribution. In some cases, the compositions can contain at least 3% mannitol.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: December 8, 2020
    Assignee: ISOThrive Inc.
    Inventors: Lee Madsen, II, Jack Oswald
  • Patent number: 10857176
    Abstract: The present disclosure relates to a method which allows direct formation of gel-like solutions of polyglucosamine at neutral pH?7 to 8, eliminating the need of prior dissolution of polyglucosamine in acidic environment; and to a homogeneous liquid combination of polyglucosamine-glyoxylate with hyaluronan.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: December 8, 2020
    Inventors: Amine Selmani, Abdellatif Chenite
  • Patent number: 10857177
    Abstract: The invention provides various isolated and synthetic forms of lipidated PSA as well as isolated or synthetic forms of the glycolipid component of lipidated PSA, and compositions thereof, methods of making including methods of isolating such forms, and methods of use thereof.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: December 8, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Sungwhan Oh, Deniz Erturk-Hasdemir, Dennis L. Kasper
  • Patent number: 10857178
    Abstract: Cerium oxide nanoparticles (CeONP) can be used to treat or prevent neurodegenerative diseases, including for example Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, AIDS-related dementia, ALS, progressive supranuclear palsy, and encephalitis, as well as mitochondrial diseases and diseases associated with mitochondrial damage. In particular, CeONP having an average size of about 2 nm to about 100 nm can be administered in an amount sufficient to block production of hydroxyl or superoxide radicals, block free radical production by A?(1-42), block A?(1-42)-induced neuronal death, block A?(1-42)-induced [Ca2+]i dysfunction in neurons, block A?(1-42)-induced lipid peroxidation, decrease loss of dopaminergic neurotransmission, or reduce mitochondrial dysfunction in a cell.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: December 8, 2020
    Assignee: EDWARD VIA VIRGINIA COLLEGE OF OSTEOPATHIC MEDICINE
    Inventors: Beverly A. Rzigalinski, Neeraj Singh, Courtney A. Cohen
  • Patent number: 10857179
    Abstract: The invention concerns a mixture or a composition, that is preferably therapeutically active by topical administration, comprising: —at least one metal salt, the metal being chosen from molybdenum (Mo), tungsten (W), vanadium (V), gold (Au), a lanthanide, in particular lanthanum; —at least one chelating agent; —at least one source of peroxidative radicals; —at least one buffer agent; and pharmaceutical compositions constituted by or comprising said mixture, the methods for producing same and applications thereof, in particular in a method for the therapeutic treatment of a viral infection, and in particular involving a virus of the Herpesviridae family; or as an anti-inflammatory.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: December 8, 2020
    Assignee: OXYMO TECHNOLOGIES INC.
    Inventors: Rémi Wilmotte, Frédéric Lorenzo, Denis Olivier Chretien
  • Patent number: 10857180
    Abstract: A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals.
    Type: Grant
    Filed: December 29, 2018
    Date of Patent: December 8, 2020
    Assignee: Vector Vitale IP LLC
    Inventors: Peter Y Novak, Maxim V Temnikov, Oleksandr Balakin
  • Patent number: 10857181
    Abstract: Cell preparations comprising a pooled and enriched, mononuclear apoptotic cell population, and a method of preparing this cell preparation are described. The pooled mononuclear apoptotic cell preparation may be obtained from pooled, allogeneic white blood cell fractions that are pooled prior to or following induction of apoptosis. Further, described herein are methods of use of these pooled apoptotic cell preparations for treating an immune disease, an inflammatory disease, an autoimmune disease, or infertility in a subject. For example, a pooled apoptotic cell preparation may be used to treat graft versus host disease (GVHD) in an allogeneic subject.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: December 8, 2020
    Assignee: ENLIVEX THERAPEUTICS LTD
    Inventors: Dror Mevorach, Shai Novik
  • Patent number: 10857182
    Abstract: Provided herein are methods of generating antigen-specific T cells for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, utilizing stem cell-like memory T cells (TSCM cells). Also disclosed are antigen-specific T cells generated by such methods, and methods of treating a human patient using such antigen-specific T cells.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: December 8, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Richard John O'Reilly, Aisha Nasreen Hasan
  • Patent number: 10857183
    Abstract: The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem/progenitor cell transplant. For example, the present disclosure provides a therapeutic population of cells, comprising an enriched population of hematopoietic stem/progenitor cells, memory T cells, regulatory T cells, and wherein the population of cells is depleted of naïve conventional ??-T cells. The present disclosure further provides methods of treatment using the therapeutic population of cells. In other embodiments, the present disclosure provides methods of producing a therapeutic population of cells.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: December 8, 2020
    Assignee: ORCA BIOSYSTEMS, INC.
    Inventors: Ivan K. Dimov, Nathaniel Fernhoff, Kevin Sheehan
  • Patent number: 10857184
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: December 8, 2020
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Patent number: 10857185
    Abstract: Cocktails of chemical inducers of neuron-like properties (CINP) is provided, which includes cAMP agonists, neurogenic small molecules, glycogen synthase kinase inhibitors, TGF? receptor inhibitors, and BET family bromodomain inhibitors and optionally, a selective inhibitor of ROCK or p38 MAPK. These cocktails are used in a method of inducing neuron-like properties in partially or completely differentiated non-neuronal cells. The method includes contacting cells of a first type (non-neuronal) with the CINPs for a sufficient period of time to result in reprogramming the cell into cells of a second type having neuron-like characteristics (CiNs). Isolated chemically induced neurons (CiNs) can be used in a number of applications, including but not limited to cell therapy.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: December 8, 2020
    Assignees: Beihao Stem Cell and Regenerative Medicine Research Institutes Co., Ltd., Peking University
    Inventors: Hongkui Deng, Xiang Li, Xiaohan Zuo
  • Patent number: 10857186
    Abstract: A traditional Chinese medicine composition for treating acute stage of cerebral infarction. The traditional Chinese medicine composition combines buffalo horns, unprocessed rehmannia roots, red paeony roots, cortex moutan, grassleaf sweelflag rhizome and turmeric root-tuber, and exerts the synergistic effects of the medicines through compatibility, thereby being capable of more effectively clearing away heat and toxic materials, cooling the blood, dissipating blood stasis and inducing resuscitation, and achieving the purpose of treating acute stage of cerebral infarction.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: December 8, 2020
    Assignee: Jiangsu Province Institute of Traditional Chinese Medicine
    Inventors: Hongquan Liu, Xiaolan Cheng, Jingbo Li, Mingming Fang, Shuting Jiang, Yudi Lu, Jie Gong
  • Patent number: 10857187
    Abstract: Brain injury can be caused by trauma or may occur in stroke or neurodegenerative diseases. The disclosure relates to compositions that can include exosomes isolated from human adipose-derived stem cells (hASC) and methods where exosomes from hASC may be used alone or in combination with insulin for the treatment of brain injury.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: December 8, 2020
    Assignee: University of South Florida
    Inventors: Niketa A. Patel, Paula Cole Bickford
  • Patent number: 10857188
    Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: December 8, 2020
    Assignee: Crestovo Holdings LLC
    Inventor: Thomas Julius Borody
  • Patent number: 10857189
    Abstract: A method for preventing and/or treating vitamin B12 deficiency is taught. The method comprises administering a composition comprising pseudovitamin B12-producing bacteria, optionally in conjunction with mucin-degrading and/or propionate-producing bacteria, to a subject in need thereof. The method is particularly suitable for administration to subjects suffering from vitamin B12 deficiency due to metformin treatment for type-2 diabetes, and to subjects having undergone bariatric surgery.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: December 8, 2020
    Assignee: Caelus Pharmaceuticals B.V.
    Inventor: Willem Meindert De Vos
  • Patent number: 10857190
    Abstract: Bacterial hyperswarmers are disclosed for treatment, prevention and diagnosis conditions such as intestinal inflammation.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: December 8, 2020
    Assignee: Albert Einstein College of Medicine
    Inventors: Sridhar Mani, Libusha Kelly, Hao Li
  • Patent number: 10857191
    Abstract: Provided herein are methods of using therapeutically effective compositions of sandalwood oil to treat oral mucositis.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: December 8, 2020
    Assignee: SANTALIS PHARMACEUTICALS, INC.
    Inventors: Corey Levenson, Paul Castella, Ian Clements
  • Patent number: 10857192
    Abstract: This invention relates to the use Pulicaria incisa (Pi) infusion for granting cells and tissues with anti-oxidative effect. The invention further relates to the use Pulicaria incisa (Pi) infusion for treating neuroinflammatory conditions. The invention further relates to cultivated Pi in treating neuroinflammatory conditions and producing anti-oxidative effect.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: December 8, 2020
    Assignee: THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION
    Inventors: Anat Elmann, Rivka Ofir
  • Patent number: 10857193
    Abstract: Cactus pear (Opuntia) extract compositions, their methods of preparation, and their uses in products are provided. The Opuntia extract compositions are a mixture of an extract prepared by extraction of Opuntia fruit/fruit parts, combined with an extract prepared by extraction of Opuntia cladodes/cladode parts. The resulting Opuntia extract compositions exhibit improved therapeutic characteristics as compared with known Opuntia fruit juices or extracts, including increased hypoglycemic effects.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: December 8, 2020
    Assignee: FINZELBERG GMBH & CO. KG
    Inventors: Ivo Pischel, Bjoern Feistel, Bernd Walbroel
  • Patent number: 10857194
    Abstract: A hybrid herbal and drug composition includes an amount of Chinese herb about 0.01 to 5% by weight of the composition; an amount of animal-based matter about 0.01 to 5% by weight of the composition; an amount of vitamin about 0.01 to 5% by weight of the composition; an amount of mineral about 0.01 to 5% by weight of the composition; an amount of hormone about 0.01 to 5% by weight of the composition; an amount of factory produced product about 0.01 to 5% by weight of the composition; and an amount of the purified water about 70% to 99.94% by weight of the composition.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: December 8, 2020
    Inventor: Shui Yin Lo
  • Patent number: 10857195
    Abstract: Extracts of plants of the Lamiaceae family, including the Mentha genus, are shown to have a positive impact on overall cognitive health, including improvements in memory, reasoning, attention/concentration, planning, mood, sleep and associated behaviors.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: December 8, 2020
    Assignee: KEMIN INDUSTRIES, INC.
    Inventors: Michael Ceddia, Kelli Herrlinger, Brandon Lewis, Shulin Feng, Kristin Nieman
  • Patent number: 10857196
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: December 8, 2020
    Assignee: BicycleTx Limited
    Inventors: Paul John Beswick, Gabriela Ivanova-Berndt, Gemma Elizabeth Mudd, Silvia Pavan, Michael Skynner, Daniel Paul Teufel, Katerine Van Rietschoten
  • Patent number: 10857197
    Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: December 8, 2020
    Assignee: THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
    Inventors: Kevin J. Tracey, Huan Yang, Yousef Al-Abed
  • Patent number: 10857198
    Abstract: The invention relates to cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection. In particular, the invention provides a cyclosporine liquid formulation for use as an aerosol for inhalation in a method of preventing or treating pulmonarychronic graft rejection in single lung transplanted patients. The formulation is preferably administered once or twice daily. The formulation may be aerosolized with a nebulizer that comprises features for monitoring the time, date and duration of inhalation by the patient, in order to monitor patient adherence. The formulation according to the invention may be combined with standard immunosuppressants and corticosteroids.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: December 8, 2020
    Assignee: BREATH THERAPEUTICS GMBH
    Inventors: Martin Knoch, Oliver Denk
  • Patent number: 10857199
    Abstract: A method of promoting hair growth can include: a polypeptide having a sequence that has at least 75% complementarity to or at least 75% identical to SPR4; and topically administering the polypeptide to a subject. This can include putting or causing the polypeptide to be in the skin, such as in any dermal layer. In one aspect, the method can include administering the composition topically so as to administer the polypeptide to the subject. In one aspect, the method can include administering the polypeptide to skin of the subject. In one aspect, the method can include administering the polypeptide to a hair follicle of the subject. In one aspect, the method can include administering the polypeptide to a bald spot of the subject.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: December 8, 2020
    Assignee: The University of Kansas
    Inventors: Peter S. N. Rowe, Aline Martin, Nicolae Valentin David, M. Laird Forrest, Kenneth Ryan Moulder, Shuang Cai, Daniel J. Aires
  • Patent number: 10857200
    Abstract: This invention relates, in part, to methods and compositions that are useful for the treatment and/or prevention of various disorders, including radiation-related disorders, such as acute radiation syndrome.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: December 8, 2020
    Assignee: Cleveland BioLabs, Inc.
    Inventors: Vadim Krivokrysenko, Elena Feinstein
  • Patent number: 10857201
    Abstract: Neonatal NET-Inhibitory Factor (nNIF) and nNIF-Related Peptides (NRPs) are provided. Methods for the treatment of and prophylaxis against inflammatory disorders and cancer are also provided. Additionally, methods for the inhibition of metastasis in patients having cancer are provided. The methods can include administering nNIF and/or a NRP to patients having, or at risk of developing, an inflammatory disorder or a cancer.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: December 8, 2020
    Assignee: Ballard Spahr LLP
    Inventors: Christian Con Yost, Guy A. Zimmerman, Andrew S. Weyrich, Joshua Schiffman
  • Patent number: 10857202
    Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot # P05112 and/or the ligand of Uniprot # P35225 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the Th2 immune response. In some embodiments, administration is preferably locally to the lung in order to treat, ameliorate or prevent allergic asthma, rhinitis, conjunctivitis, lung fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary alveolar proteinosis or adult respiratory distress syndrome.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: December 8, 2020
    Inventors: Andreas Hohlbaum, Laurent Audoly, Beverly Koller
  • Patent number: 10857203
    Abstract: Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: December 8, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
  • Patent number: 10857204
    Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl l, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: December 8, 2020
    Assignee: TerSera Therapeutics LLC
    Inventors: David J. Ellis, George P. Miljanich, David E. Shields
  • Patent number: 10857205
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: December 8, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: George D. Yancopoulos
  • Patent number: 10857206
    Abstract: A method of preventing or treating cutaneous pigmentation disease in a subject in need thereof, includes: providing a pharmaceutical composition comprising SDF1, an inducer or activator of SDF1, as an active ingredient; and administering the pharmaceutical composition to the subject, wherein the cutaneous pigmentation is prevented or treated, and the cutaneous pigmentation disease is selected from the group consisting of melasma, freckles, lentigo, nevus, pigmentation by drugs, pigmentation after inflammation and hyperpigmentation incurred from dermatitis.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: December 8, 2020
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Hee Young Kang, Tae Jun Park, Jung Eun Yoon, Mi Sun Kim
  • Patent number: 10857207
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: December 8, 2020
    Assignee: MannKind Corporation
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Patent number: 10857208
    Abstract: Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: December 8, 2020
    Assignee: CLINUVEL PHARMACEUTICALS LIMITED
    Inventors: Michael John Kleinig, Thomas R. Tice, Jay K. Staas
  • Patent number: 10857209
    Abstract: Methods of cancer treatment are disclosed. Particularly, disclosed herein are methods of administering LAL and PPAR? ligands for treating various cancer patients to promote anti-cancer immunity (suppress MDSC), use for inhibiting tumor progression, and use for inhibiting tumor metastasis.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: December 8, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Cong Yan, Hong Du
  • Patent number: 10857210
    Abstract: Compositions and methods to promote wound healing are described. The compositions and methods up-regulate X-box binding protein 1 (XBP1) and/or inositol-requiring enzyme-1 (IRE-1). In various embodiments, the compositions and methods can be used to promote wound healing in diabetic subjects.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: December 8, 2020
    Assignee: Wayne State University
    Inventors: Kezhong Zhang, Jiemei Wang
  • Patent number: 10857211
    Abstract: Markers for genomic instability in Fanconi Anemia (FA) and other pathologies for therapeutic and diagnostic uses. In one embodiment, glycosphingolipid metabolism is altered in the FA deficient squamous cell carcinoma (SCC) cells, based on analysis of a metabolomics/lipidomics platform. The data indicated ganglioside metabolism was important in FA patients' susceptibility to SCC progression.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: December 8, 2020
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Susanne I. Wells, Kenneth D. R. Setchell, Lindsey Romick-Rosendale, Wujuan Zhang, Xueheng Zhao
  • Patent number: 10857212
    Abstract: A method for treating Pompe disease including administration of recombinant human acid ?-glucosidase having optimal glycosylation with mannose-6-phosphate residues in combination with an amount of miglustat effective to maximize tissue uptake of recombinant human acid ?-glucosidase while minimizing inhibition of the enzymatic activity of the recombinant human acid ?-glucosidase is provided.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: December 8, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Hung V. Do, Richie Khanna, Russell Gotschall